{"analyses":[{"ciLowerLimit":"0.297","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.809","estimateComment":"Stratified HR, i.e., based on analysis stratified by randomization stratification factors.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0021","paramType":"Hazard Ratio (HR)","paramValue":"0.490","statisticalMethod":"1-sided stratified log-rank p-value"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"8.0","value":"5.4"},{"groupId":"OG001","lowerLimit":"2.2","upperLimit":"6.6","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"DoR was defined as time from date of first response in responders (CR/CRi per Investigator assessment) to date of PFS event (i.e. death, progressive disease \\[objective progression, relapse from CR/CRi or treatment discontinuation due to global deterioration of health status\\] or starting new induction therapy or post-therapy stem cell transplant \\[SCT\\] without achieving CR/CRi). Responders without PFS events were censored at the last valid disease assessment including follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with inotuzumab ozogamicin at a starting dose of 1.8 mg/m\\^2 (according to body surface area) per cycle with a divided-dose regimen using 3 weekly administrations. Participants received 0.8 mg/m\\^2/cycle on Week 1 (Day 1), followed by 0.5 mg/m\\^2 on Week 2 (Day 8) and Week 3 (Day 15) of a 21-day cycle, and administered as an intravenous infusion over 60 minutes. For participants who achieved a CR or CRi, or to allow recovery from toxicity, the length of Cycle 1 could be extended up to 28 days (ie, 1 week treatment-free interval starting on Day 21). For participants who achieved CR or CRi, the inotuzumab ozogamicin dose administered on Week 1 was reduced to 0.5 mg/m\\^2 (for a total cycle dose of 1.5 mg/m\\^2/cycle) for Cycles 2 through 6 (maximum number of cycles permitted). For Cycles 2 through 6, the cycle length was 28 days for all participants (regardless of remission status).","id":"OG000","title":"Inotuzumab Ozogamicin"},{"description":"Participants received fludarabine, cytarabine, granulocyte-colony stimulating factor (FLAG), mitoxantrone + cytarabine (MXN/Ara-C), or high-dose cytarabine (HIDAC), according to the Investigator's choice.","id":"OG001","title":"Defined Investigator's Choice of Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Participants in the ITT218 population who achieved CR/CRi","reportingStatus":"POSTED","timeFrame":"Up to 2 years from randomization","title":"Duration of Remission (DoR) for Participants Who Achieved CR/CRi (Per Investigator Assessment)","type":"SECONDARY","unitOfMeasure":"Months"}